Login to Your Account

TG seeks twofer in SPA for combo CLL phase III trial

By Marie Powers
News Editor

Thursday, September 17, 2015

TG Therapeutics Inc. will seek to carry two candidates in its pipeline across the goal line in a single play after reaching agreement with the FDA on an SPA for the design of a phase III study combining TG-1101 and TGR-1202 to treat chronic lymphocytic leukemia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription